Cargando…

Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant

This study investigates early cardiac events (ECEs) occurring during the first 180 days after allogeneic hematopoietic cell transplant (allo-HCT) in 416 adults receiving posttransplant cyclophosphamide (PTCY) (n = 258) or not receiving PTCY (n = 158). Total body irradiation (TBI) was given to 133 (3...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Valencia, Amanda Isabel, Cascos, Enric, Carbonell-Ordeig, Sara, Charry, Paola, Gómez-Hernando, Marta, Rodríguez-Lobato, Luis Gerardo, Suárez-Lledó, María, Martínez-Cibrian, Nuria, Antelo, María Gabriela, Solano, María Teresa, Arcarons, Jordi, Nomdedeu, Meritxell, Cid, Joan, Lozano, Miquel, Díaz-Ricart, Maribel, Rosiñol, Laura, Esteve, Jordi, Urbano-Ispizua, Álvaro, Carreras, Enric, Martínez, Carmen, Fernández-Avilés, Francesc, Rovira, Montserrat, Salas, María Queralt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188633/
https://www.ncbi.nlm.nih.gov/pubmed/36453637
http://dx.doi.org/10.1182/bloodadvances.2022008792
Descripción
Sumario:This study investigates early cardiac events (ECEs) occurring during the first 180 days after allogeneic hematopoietic cell transplant (allo-HCT) in 416 adults receiving posttransplant cyclophosphamide (PTCY) (n = 258) or not receiving PTCY (n = 158). Total body irradiation (TBI) was given to 133 (31.9%) patients, of whom 111 (83.4%) received TBI combined with PTCY. The day +180 cumulative incidence function (CIF) of ECEs was 8.4%, with heart failure (n = 13) and pericardial complications (n = 11) being the most prevalent complications. The incidence of ECEs was higher in patients receiving PTCY, and receiving TBI. ECEs were more prevalent in haploidentical HCTs than in matched sibling donor, 10/10 HLA-matched unrelated donor, and 9/10 HLA-mismatched unrelated donor allo-HCTs. As for the ECE risk from the combination of PTCY and TBI, the multivariate analysis reported that patients receiving PTCY without TBI, TBI without PTCY, and TBI with PTCY were at higher risk for ECEs compared with patients receiving neither PTCY nor TBI. Pre-existing cardiac morbidity predicted ECEs. However, using high-dose CY-containing preparative regimens did not increase the risk for cardiac toxicity at +180 days after allo-HCT. ECEs were associated with higher nonrelapse mortality and lower overall survival. Considering that PTCY and TBI were predictors for ECEs, and the impact of this complication on transplant mortality, the implementation of cardiac monitoring plans could be appropriate in patients receiving these medications.